Alzheimer’s disease, frontotemporal dementias, progressive supranuclear palsy, Corticobasal degeneration, Clinical Trial Study
< Back to Find a Trial

A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer’s Disease - BAN2401-G000-3011 (Eisai)

ID
NCT03887455
Condition Studied
Alzheimer's Disease
Phase
Phase III
Status
Active, but no longer recruiting
Intervention
BAN2401
Principal Investigator
Sponsor
Eisai Inc.
Contact Coordinator

Please go to ClinicalTrials.gov for more information.